IPAX BrIGHTNCT07100730
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Telix Pharmaceuticals (Innovations) Pty Limited
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jul 2027 to Jul 2028 Show 5 more changesShow less
- Eligibility criteria expanded, about 29 words
- Study completion pushed from Nov 2027 to Nov 2028
- Enrollment target: 50 to 51
- Secondary endpoints: details revised at 3 of 3 entries
- Study sites revised (9)
- Minor Trial sites expanded: 4 → 9 locationsv6
- Minor Site details revised at 1 of 4 sitesv5
- Minor Study sites: 3 to 4v4
- Minor Study sites: 2 to 3v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Start date changed from estimate of Sep 1, 2025 to Nov 2, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and Tolerability
Timeframe: Through study completion, an average of 2 years
Dose Optimization
Timeframe: Through study completion, an average of 2 years
Secondary (3)
TLX101-Tx Concentration in the blood
Radiation Dosimetry
TLX101-Tx Concentration in the Urine
Arms and interventions
TLX101-Tx + Standard of CareExperimental
TLX101-Tx + Lomustine
TLX101-Tx OnlyExperimental
TLX101-Tx Therapy only
Combination products: TLX-101-Tx + Lomustine
Radiation: TLX101-Tx
Sites
9 sites in 4 countries
Australia 4, Belgium 2, Netherlands 2, Austria 1